Pricing Log in Create free account

Evogene Ltd. (EVGN) vs NeuroSense Therapeutics Ltd. (NRSN)

Evogene Ltd. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Evogene Ltd. and NeuroSense Therapeutics Ltd. are of similar size ($6.3M and $6.0M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −547.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, NeuroSense Therapeutics Ltd. leads on 6 and Evogene Ltd. on 4.

Valuation

Metric EVGN NRSN Biotechnology median
P/E n/m n/m 8.50
P/S 2.87 n/m 9.71
P/B 0.82 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.43 n/m 0.64
EV/Sales (2.77) n/m 9.21
Earnings yield (233.33%) (406.90%) (33.15%)
Free cash flow yield (226.59%) (444.35%) (25.50%)

Profitability

Metric EVGN NRSN Biotechnology median
Gross margin (67.59%) — 65.16%
Operating margin (851.42%) 0.00% 0.00%
Net margin (547.62%) 0.00% 0.00%
Free cash flow margin (650.63%) 0.00% 0.00%
Return on equity (100.03%) 0.00% (56.36%)
Return on assets (38.31%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EVGN NRSN Biotechnology median
Revenue growth (TTM) (54.71%) — 6.02%
EPS growth (last fiscal year) 62.63% 18.52% 30.26%
Revenue growth, 5-year CAGR 29.94% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EVGN NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.57 0.28 4.72
Net debt to EBITDA 1.12 0.01 0.96

Dividend

Metric EVGN NRSN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric EVGN NRSN Biotechnology median
Market cap 6.32m 6.01m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack